Abstract |
No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced HCC and well-preserved liver function, whilst the evidence about its effectiveness in patients with more severe liver impairment is less robust. A randomized trial to demonstrate the efficacy of sorafenib in Child-Pugh B patients with advanced HCC is currently ongoing. In the meantime, several trials are testing the role of sorafenib in early HCC (as adjuvant treatment after potentially curative loco-regional therapies) and in intermediate stage (exploring different modalities of integration of sorafenib with trans-arterial chemo-embolization). The results of all these trials will better define the potentiality and the boundaries of use of sorafenib in HCC patients.
|
Authors | Massimo Di Maio, Gennaro Daniele, Maria Carmela Piccirillo, Pasqualina Giordano, Giuseppe Signoriello, Bruno Daniele, Francesco Perrone |
Journal | Cancers
(Cancers (Basel))
Vol. 4
Issue 2
Pg. 549-65
(Jun 05 2012)
ISSN: 2072-6694 [Print] Switzerland |
PMID | 24213324
(Publication Type: Journal Article)
|